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Oligometastastic disease is assumed to be an ex-
pression of biological indolent metastatic disease, 
that is a low burden and has little effect on patient’s 
performance status. However, there is no consen-
sus on the definition or means needed to diagnose 
these favorable metastatic patients [1]. The optimal 
management of oligo-recurrent prostate cancer is 
also an ongoing area of controversy. The traditional 
treatment approach for favorable metastatic disease 
has been conservative and favored observation and 
then systemic or palliative therapy [2]. Low burden 
disease among other considerations, including ad-
AbstrAct
background: In the current study we evaluated 68Ga psMa peT/ cT to measure local control of bone metastasis in oligometa-
static prostate cancer patients treated with sBrT.  
Materials and methods: after the institutional review board approval, a retrospective review of medical records of consecu-
tive prostate cancer patients treated between 2014 and 2018 was conducted. Only medical records of patients that were 
treated with sBrT for bone metastasis and had pre-and post-sBrT 68Ga psMa peT/cT scans were included in our study. 
Data extracted from the medical files included patient-related (age), disease-related (Gleason score, site of metastasis), and 
treatment-related factors and outcomes.
results: During the study period, a total of 12 patients (15 lesions) were included, with a median age of 73 years. The median 
follow-up was 26.5 months (range 13–45 months). Median time of 68Ga psMa peT/ cT follow up was 17.0 months (range 3–39 
months). The median pre-treatment psa was 2 ng/mL (range 0.56–44 ng/mL) vs. post treatment psa nadir of 0.01 ng/mL 
(0.01–4.32) with a median time to nadir of 7 months (range, 2–12). Local control was 93% during the follow up period and there 
was correlation with psMa avidity on peT. None patients developed recurrences in the treated bone. None of the patients had 
grade 3 or more toxicities during follow-up.
conclusions: sBrT is a highly effective and safe method for treatment of prostate cancer bone metastases. More studies are 
required to determine if sBrT provides greater clinical benefit than standard fractionation for oligometastatic prostate cancer 
patients. 68Ga psMa peT/cT should be further investigated for delineation and follow-up.
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vances in imaging and radiation therapy (RT) deliv-
ery, led to the increasing use of ablative treatments 
to these patients. The SABR-COMET trial [3], 
a phase II trial (21% prostate cancer) showed a sta-
tistically significant survival advantage for stereo-
tactic ablative radiation (median overall survival, 
41 months versus 28 months in the control group) 
indicates that ablative approach for oligometastatic 
disease should be further explored. 
The yield of imaging and early detection of meta-
static disease on outcome is still unclear. New Posi-
tron Emission Tomography (PET) tracers provide 
opportunities to detect oligometastases in prostate 
cancer patients, both at initial cancer diagnosis and 
at the time of biochemical failure following treat-
ment [4]. 
Prostate-Specific Membrane Antigen (PSMA) is 
a type II transmembrane protein and is typically 
overexpressed in prostate cancer tissue. 68Gallium 
(68Ga) PSMA PET/Computed Tomography (CT) 
has high sensitivity for the detection of low burden 
metastatic disease [4].
Stereotactic body radiotherapy (SBRT) is an ap-
pealing treatment option for metastasis-directed 
therapy given its non-invasive nature and short 
treatment duration. SBRT delivers ablative radia-
tion doses to smaller volumes with an intent to 
eradicate the low burden disease and achieve bet-
ter local control and, hopefully, survival or even 
cure [3]. The approach for bone metastases is also 
dictated by the area of the skeleton that is involved. 
Vertebra and weight baring bone disease involve-
ment necessitate an evaluation for the need of fixa-
tion to reduce the risk for pathological fracture. 
In cases of RT to treat bone metastases, the tra-
ditional RT volumes targeted the entire involved 
bone using palliative “conventional” doses (even 
if hypofractionation/single fraction was used, the 
total dose was relatively low) frequently resulting 
in suboptimal long-term local control. SBRT for 
spine metastasis is commonly used and is consid-
ered as one of the standard treatments for spine 
bone metastases in the setting of newly diagnosed 
disease, recurrent or progressive disease after prior 
RT, or post-surgery [5]. However, data on SBRT 
for non-spine bone metastases are scarce overall 
and cannot be regarded as the standard of care [6]. 
A few clinical series have reported excellent local 
control following SBRT using compound tomog-
raphy (CT) or magnetic resonance (MRI) to guide 
treatment planning [7]. There is, however, a paucity 
of studies that have used molecular imaging to as-
sess response to SBRT in the bone. Furthermore, 
there are no consensus guidelines on how to define 
the target volumes for SBRT in the non-spine bone 
metastases [6, 8].
In the current study, we evaluated 68Ga PSMA 
PET/CT to measure local control of bone metas-
tasis in oligometastatic prostate cancer patients 
treated with SBRT. 
Material and methods
After the institutional review board approval, 
a retrospective review of medical records of con-
secutive prostate cancer patients treated between 
2014 and 2018 was conducted. Only the medical 
records of patients that were treated with SBRT 
for oligometastatic bone lesions (defined as up to 
3 metastasis) and had pre- and post-SBRT 68Ga 
PSMA PET/CT scans were included in our study. 
Data extracted from the medical files included pa-
tient-related (age), disease-related (Gleason score, 
site of metastasis), and treatment-related factors 
and outcomes. 
Ga 68-PSMA PET-CT scanning was performed 
using a combined PET-CT protocol with a 16-de-
tector-row helical CT scanner (Gemini GXL, Phil-
lips Healthcare). This scanner enables simultaneous 
acquisition of up to 45 trans-axial PET images with 
interslice spacing of 5 mm in one bed position and 
provides an image from the vertex to the thigh in 
about 10 bed positions. The trans-axial fields of 
view and pixel sizes of the PET images reconstruct-
ed for the fusion were 57.6 cm and 4 mm, respec-
tively, with a matrix size of 144 × 144. The CT com-
ponent was performed with oral and intravenous 
contrast media. The following technical parameters 
were used for CT imaging: pitch 0.8, gantry rotation 
speed 0.5, 120 kVp, 250 mAs, 3-mm slice thick-
ness and specific breath-holding instructions. Each 
patient received an intravenous injection of 148 
MBq Ga 68–PSMA. About 60 min later, CT images 
were obtained from the vertex to the mid-thigh 
for about 32 sec. A contrast-enhanced CT scan 
was obtained 60 sec after injection of 2 mL/kg of 
non-ionic contrast material (CM) (Omnipaque 370 
GE Healthcare). An emission PET scan followed in 
3D acquisition mode for the same axial image range 
of 2.0–2.5 min per bed position. The diagnostic CT 
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images were used for the fusion with the PET data, 
as well as to generate a map for attenuation correc-
tion. PET images were reconstructed using a line of 
response protocol with CT attenuation correction, 
and the reconstructed images were generated for 
review on a computer workstation (EWB, Extended 
Brilliance Workstation, Philips Healthcare). 
All available images were interpreted by experi-
enced specialists in nuclear medicine and radiol-
ogy and reviewed by one of the study co-authors. 
Ga 68–PSMA activity was quantified by calculating 
a maximum standardized uptake value (SUVmax). 
Focally increased PSMA uptake, not explained by 
the normal bio-distribution of PSMA, was consid-
ered positive.   
Pre- and post-SBRT 68Ga PSMA PET/CT scans 
were reviewed and classified by a nuclear medicine 
and radiology specialist (YE) to determine local 
control at the target volume [bone enclosed by the 
SBRT prescription isodose line (= in-field con-
trol)]. Local control/tumor response to SBRT was 
classified as follows: (a) complete response (CR) 
— post-treatment max standardized uptake volume 
(SUVmaxpost) equal to the SUV mean in normal 
bone (SUV-NB); (b) partial response (PR) — SU-
Vmaxpost was less than previous SUV max (SUV-
maxpre), but was greater than the SUV-NB (c) no 
Response (NR) — SUVmaxpost was equal or greater 
than SUVmaxpre. 
Our department’s protocol for SBRT bone me-
tastasis includes the following: planning CT is 
performed without IV contrast with 1.0–1.5 mm 
slice thickness. Immobilization was with 
a Vac-Lok™ [CIVCO® Radiotherapy]. For target 
delineation, 68Ga PSMA PET/CT is fused onto 
the planning CT. Gross tumor volume (GTV) is 
delineated manually from attenuation corrected 
PSMA images superimposed on full dose CT, pro-
viding anatomical boundaries to the PET posi-
tive regions [9]. The clinical target volume (CTV) 
for vertebral lesions was segmented according to 
International Spine Radiosurgery Consortium 
(ISRC) recommendations [5]. For non-spine le-
sions, the CTV was a 2 cm expansion of the GTV 
around the lesion in the involved bone, no expan-
sion into soft tissue, and without expansion for 
PTV. The prescription dose for this CTV was 3 
fractions of 9–10 Gy delivered twice a week for 13 
of the 15 lesions (Tab. 1) 
RT delivery included 21iX and Trilogy machines 
(Varian Medical Systems, Palo Alto, CA, USA) us-
ing RapidArc® (VMAT) Radiotherapy Technology 
guided with Cone Beam CT (CBCT) and orthogo-
nal images prior to each fraction. 
Our follow-up protocol includes a clinical evalu-
ation every 6 months (history and physical exam) 
and serum PSA. Repeat 68Ga PSMA PET/CT scans 
were performed for patients with rising PSA fol-
lowing SBRT in order to re-stage the patient prior 
to the choice of therapy, and in some cases were 
performed to assess response to therapy without 
evidence of biochemical failure.  




Fx dose × 






Gleason T stage Age (yrs)
0.01 2.09 10 Gy × 3 Yes Ilium XrT + aDT 8 T3a 72
0.06 6.30 6 Gy × 6 Yes Ilium, L5 surgery 7 T3B 73
4.32 21 10 Gy × 3 Yes D11 XrT 7 T1c 74
1.52 3.50 10 Gy × 3 No Ilium, L3 XrT 7 T2B 83
0.12 1.60 9 Gy × 3 No D12 XrT + aDT 10 T2B 72
0.16 0.65 10 Gy × 3 No D6 Brachytherapy 6 T1c 74
1.7 1.48 10 Gy × 3 Yes D7, Ilium surgery 7 T2c 64
0.06 5.3 8 Gy × 5 Yes pubis surgery 7 – 76
1 3.45 10 Gy × 3 No scapula XrT + aDT 9 T2a 76
0.01 44.9 10 Gy × 3 Yes D12 XrT + aDT 9 T3a 86
0.47 12.6 10 Gy × 3 Yes D8, D10 XrT + aDT 7 T2B 76
0.05 21.5 10 Gy × 3 Yes rib surgery 9 T3a 52
XrT — external beam radiation; aDT — androgen deprivation therapy; Gy — Gray; psa units — ng/mL; Fx — fraction
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results
During the study period, a total of 12 patients 
(15 lesions) were included, with a median age of 
73 years. The median follow-up was 26.5 months 
(range 13–45 months). Median time of 68Ga PSMA 
PET/CT follow up was 17months (range 3–39 
months). Patients’ and treatment characteristics are 
summarized in Table 1. None of the patients died 
during the study period. 
The median pre-treatment PSA was 2 ng/mL 
(range 0.56–44 ng/mL) vs. post treatment PSA na-
dir of 0.01 ng/mL (0.01–4.32) with a median time 
to nadir of 7 months (range, 2–12). 
Median SUVmax pre was 5.74 (range 2.15–13.0). 
Complete response on repeat PSMA PT/CT was 
observed in 14 of 15 (93%) lesions, with reduction 
in the median SUVmaxpre RT from 5.74 to 1.16 SU-
Vmaxpost RT (p < 0,0003) (Fig. 2). One lesion had 
(PR) residual PSMA avidity which increased over 
time. Figure 3 shows repeat 68Ga PSMA PET/ CT 
scans pre-SBRT and 3 and 6 months after radiation, 
demonstrating decreasing avidity over time. Out of 
12 patients, 5 (41.6%) remained free of new metas-
tasis at 2 years, 5 developed up to 3 additional me-
tastases at other sites (oligometastatic disease) and 
2 patients developed widespread metastatic disease. 
No patients developed recurrences in the treated 
bone. Transient grade 2 esophagitis was reported in 
3 patients treated to metastasis in the dorsal spine. 
None of the patients had grade 3 or more toxicity 
related to radiotherapy during follow-up. 
Discussion
Our study demonstrated an excellent outcome 
of SBRT for prostate cancer bone metastasis. Com-
plete local response of the bone lesion was demon-
strated by SUVmaxpost equal to the mean SUV in 
normal bone (SUV-NB) and correlated to clinical 
outcome (patient’s clinical evaluation).
Although our cohort is small, our study rais-
es a few clinically relevant issues. SBRT to the 
bone lesions resulted in CR in 93% of the patients 
(similar rates were reported by Siva [10]). None 
of the patients failed in the treated bone (=no 
re-treatment), developed a fracture, or suffered 
from treatment related complications. At a me-
dian follow up of 26.5 months, all patients were 
still alive, suggesting that this patient population 
should be offered treatment that provides good 
local control.  Conventional fractionation to bone 
metastases, as indicated by Tong et al. [11], was 
reported to provide CR in 49% to 61% of patients. 
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It is difficult to compare CR results to older trials 
of conventional fractionation evaluating response 
as different definitions and imaging (if any) were 
used (e.g., re-treatment, pain relief). Moreover, 
imaging based-morphological evaluation of bone 
metastases can be challenging. In prostate can-
cer patients, the response is evaluated via PSA 
levels and standard CT imaging using response 
evaluation criteria in solid tumors (RECIST) cri-
teria [12]. Prostate cancer bone metastases usually 
cause osteoblastic response which is irreversible 
and may or may not harbor viable cancer cells, 
thus, making it difficult to assess using RECIST 
[13]. The use of molecular imaging using 68Ga 
PSMA PET/CT, as shown in our study, should be 
further evaluated as an innovative method to plan 
a B
Figure 2. A. The slope of the decline in psa (two points: pretreatment psa and psa nadir) following sBrT for each patient 
and the corresponding line in panel; b. The decline in sUVmax uptake (two points: pre/post treatment sUVmax)
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the target volume and evaluate response to SBRT 
[12].
In our study the CTV was 2 cm around the GTV, 
along the involved bone without a PTV. A 2 cm 
margin is relatively larger than what is reported in 
the literature [6, 8, 14]. As shown from our results, 
it was not associated with toxicity and could be 
related to the good local control and bone control. 
The use of 68Ga PSMA PET/CT for planning was 
mainly for correct delineation of the GTV rather 
than reducing margins. 
The utilization of SBRT for oligometastatic dis-
ease in prostate cancer has been studied in a num-
ber of recently published trials. The STOMP trial 
[15] utilized metastasis directed therapy with sur-
gery or SBRT without androgen deprivation thera-
py for oligometastatic prostate cancer. Patients were 
randomized to local treatment or surveillance and 
the primary endpoint was defined as androgen de-
privation therapy — free survival. The utilization 
of local therapy significantly delayed the need for 
androgen deprivation therapy which was mandated 
for symptomatic progression, occurrence of more 
than three metastases or local progression of known 
metastasis. The ORIOLE trial [16] randomized men 
with up to three metastases detected with standard 
imaging to observation versus SBRT delivered to 
all detected metastases after further evaluation with 
PSMA PET imaging. Progression at six months oc-
curred in 60% of men under observation versus 
only 19% of men who received SBRT. Mazolla et 
al. [17] performed a retrospective analysis of PS-
MA-PET guided versus choline-PET guided SBRT, 
demonstrating superior control for PSMA. These 
studies suggest a role for PET PSMA guided metas-
tasis directed therapy in men with oligometastatic 
prostate cancer. This approach may facilitate the 
delay of the need for androgen deprivation and, 
thus, perhaps be associated with improved quality 
of life and delay of onset of androgen independent 
disease. Biomarkers in the Oriole trial suggest that 
SBRT induced a systemic immune effect, warrant-
ing further study of this strategy.   
The current study has several limitations. It is 
a small retrospective study with a moderate follow 
up of 25 months. It differs from both the STOMP 
and ORIOLE trials in that eight of twelve patients 
on study received short term androgen deprivation 
of 3 months concurrently with SBRT which was 
discontinued after the completion of radiotherapy 
Thus, it is not possible to rule out a radio-sensitiz-
ing effect of concomitant ADT. This study raises 
important clinical issues that should be further in-
vestigated in clinical trials.
conclusions
SBRT is a highly effective and safe method for 
treatment of prostate cancer bone metastases. More 
studies are required to determine if SBRT provides 
greater clinical benefit than standard fractionation 
for oligometastatic prostate cancer patients. 68Ga 
PSMA PET/CT should be further investigated for 
delineation and follow up. Whether the optimal ap-
proach to oligometastatic recurrence is SBRT alone 
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